Discovery of Clinical Candidate (1R,4r)-4-((R)-2-((S)-6-Fluoro-5H-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl)cyclohexan-1-ol (Navoximod), a Potent and Selective Inhibitor of Indoleamine 2,3-Dioxygenase 1-Reference-Cited by-同舟云学术

Discovery of Clinical Candidate (1R,4r)-4-((R)-2-((S)-6-Fluoro-5H-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl)cyclohexan-1-ol (Navoximod), a Potent and Selective Inhibitor of Indoleamine 2,3-Dioxygenase 1

Published:2019-06-18 Issue:14 Volume:62 Page:6705-6733
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Kumar Sanjeev¹,Waldo Jesse P.¹,Jaipuri Firoz A.¹,Marcinowicz Agnieszka¹,Van Allen Clarissa¹,Adams James¹,Kesharwani Tanay¹^ORCID,Zhang Xiaoxia¹,Metz Richard¹,Oh Angela J.²,Harris Seth F.²,Mautino Mario R.¹^ORCID

Affiliation:

1. NewLink Genetics Corporation, Ames, Iowa 50010, United States

2. Structural Biology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States

Funder

Biological and Environmental Research

Basic Energy Sciences

National Institute of General Medical Sciences

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link